halfan and Apokyn Interactions

Interactions between halfan(halofantrine) and Apokyn (apomorphine)

halofantrine and apomorphine (Major Drug-Drug)

CONTRAINDICATED: Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.

MANAGEMENT: The concurrent use of halofantrine with other medications that can prolong the QT interval is considered contraindicated. Halofantrine should also not be given to patients who have previously taken mefloquine. The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.